What happened
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) said preliminary fourth-quarter product revenue was $3.8 million. That was up 38.4% from $2.7 million a year earlier.
The company also said full-year product revenue should be about $10.5 million. That would put it at the top of guidance and up 15.6% from the prior year.
About $1.0 million shipped in September 2026. The remaining $3.6 million is expected to begin shipping in the first quarter of fiscal 2027 and into the second quarter, subject to manufacturing and delivery schedules.
NeuroOne said the order gives it more visibility into shipments, cash flow and revenue opportunities as fiscal 2027 begins.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Preliminary Q4 FY2026 product revenue | $3.8 million | from $2.7 million, +38.4% | Press release, dated October 5, 2026 |
| Preliminary FY2026 product revenue | $10.5 million | +15.6% | Press release, dated October 5, 2026 |
| Record product purchase order | $4.5 million | Press release, dated October 5, 2026 | |
| Order shipped in September 2026 | $1.0 million | Press release, dated October 5, 2026 | |
| Remaining order expected to ship | $3.6 million | Press release, dated October 5, 2026 | |
| Open purchase orders through Q1 fiscal 2027 | $5.4 million | Press release, dated October 5, 2026 |
Read more: NeuroOne Medical Technologies (NMTC) stock analysis and investment case
Why it matters
OptimistFi's case is that NeuroOne needs product revenue and orders to keep building the business. This filing strengthens that case because revenue reached the top of guidance and the company booked a record order.
Full-year product revenue came in at about $10.5 million, the top of the previously announced $9.2 million to $10.5 million range. The company also said product orders rose 24.2% in fiscal 2026 from fiscal 2025.
NeuroOne said total open purchase orders for shipments through the first quarter of fiscal 2027 reached $5.4 million as of September 30, 2026. OptimistFi's calculation shows fourth-quarter product revenue rose by about $1.1 million from about $2.7 million a year earlier.
That helps show the pace of growth. But the figures are preliminary and unaudited. The filing also says the remaining $3.6 million is still subject to manufacturing and delivery schedules.
Browse: stock research on every company OptimistFi covers
What's next
NeuroOne said complete fourth-quarter and full-year fiscal 2026 results are expected in December 2026 with its Annual Report on Form 10-K. The preliminary figures are still subject to year-end accounting and audit procedures, so the final numbers can change. Investors will then be able to compare the preview with the audited filing. That will show whether the record order converted into shipped revenue on schedule.
More from OptimistFi
- NMTC stock: the NeuroOne Medical Technologies thesis, its status and the next test to watch
- United States Brent Oil Fund, LP (NYSE Arca: BNO) Tracks a Supply Gap
- Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze
- Meta Platforms, Inc. (NASDAQ: META) Has a Conditional $18 Billion Bill
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- NeuroOne press release, dated October 5, 2026 — Furnished as Exhibit 99.1 to the Form 8-K and containing the preliminary product revenue and purchase-order update.
- NeuroOne Form 8-K, October 5, 2026 — Current report announcing the preliminary fiscal Q4 and FY2026 product revenue and the $4.5 million purchase order.
Read the full OptimistFi thesis on NeuroOne Medical Technologies Corporation: https://optimistfi.com/stocks/NMTC
See what would break the NeuroOne Medical Technologies Corporation thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full NeuroOne Medical Technologies Corporation investment case, its status and the next test to watch live on the NeuroOne Medical Technologies Corporation thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
